DefiniGEN

DefiniGEN is excited to announce our participation in the upcoming ELRIG German Forum: Target Innovation & Novel Screening Technologies ⏰ February 18, 2025 🌍 VKU Forum, Berlin The forum will focus on pioneering therapeutic targets and the latest methodologies propelling advancements in drug discovery through cutting-edge approaches and technological innovations that are expanding the tractable target space. At DefiniGEN, we specialize in providing human-relevant, induced pluripotent stem cell (iPSC)-derived hepatocytes and disease models. Our solutions are designed to enhance the predictability and efficiency of drug discovery pipelines. We invite you to meet with our team, Ioannis Kasioulis and Malek Haddad to learn more about our offerings and discuss how our iPSC-derived models can accelerate your research. To schedule a meeting with our team during the forum, please contact us through our website here: https://lnkd.in/e9p-BzBi Join us in Berlin to explore the future of drug discovery and how DefiniGEN's innovative solutions can contribute to your success. #elrig #drugdiscovery #drugscreening #efficacyscreening #pharma #biotech #hepatocyes #liver #stemcells #iPSCs #liverdisease #masld

Collaboration is at the heart of all great scientific accomplishments. By working with Atelerix Ltd. we can now transport Opti-HEP and disease models by encapsulating them in Aterlerix’s hydrogel in 96-well plates under normoxic conditions. What this means for our clients: ✅ This innovation allows for the transport of plates over long distance for large-scale screening, efficacy and predictive toxicology studies. ✅ The live plate format removes the variation introduced by the cryopreservation and thawing process. ✅ Hydrogel-based encapsulation of cells shows comparable cell viability to non-encapsulated cells and comparable expression of hepatocyte maturity markers (ALB, A1AT and HNF4A). If you are in need of iPSC-derived hepatocytes and disease models, then we want to work with you. Check out our range of hepatic wild-type and disease models here: https://lnkd.in/e6fswPAn

Accelerate your research with DefiniGEN's Intestinal Organoids! Are you looking for advanced, physiologically relevant models to take your intestinal disease research or drug development to the next level? We offer high-quality human intestinal organoids derived from iPSCs, designed to provide predictive, scalable, and disease-relevant results. Why Choose our Intestinal Organoids? ✅ Precision and Relevance: Ideal for studying a wide range of intestinal diseases, including IBD, cancer, and infection. ✅ Drug Screening & Toxicology: Accelerate drug discovery with more reliable, human-relevant data. ✅ Customizable: Tailor your organoid models to specific research needs. Whether you're in academic research, biotech, or pharma, our intestinal organoids provide the cutting-edge technology you need to drive innovation in gastrointestinal health and therapeutic development. Learn more about our products and accelerate your research: https://lnkd.in/edmmXDrN #IntestinalOrganoids #OrganoidTechnology #BiomedicalResearch #DrugDiscovery #PharmaInnovation #IntestinalHealth #DefiniGEN #iPSCs #GastrointestinalResearch #stemcells

We are thrilled to announce that DefiniGEN has been featured in Nature Portfolio's Biopharma Dealmakers Journal, highlighting our innovative work in developing highly predictive in vitro liver disease models. Our platform generates induced pluripotent stem cell (iPSC)-derived hepatocytes, providing unparalleled predictivity for drug efficacy and toxicity studies. This recognition underscores our commitment to accelerating the development of effective treatments for life-threatening liver conditions. Read the full article here: https://lnkd.in/erJ334qi And learn more about our platform: https://lnkd.in/dsVg46U3 #DefiniGEN #BiopharmaDealmakers #LiverDisease #DrugDevelopment #iPSC #StemCells #Biotechnology #Pharmaceuticals #HealthcareInnovation #hepatocytes

🔬 Accelerate Drug Discovery with Predictive Efficacy Screening 🔬 Traditional animal models and primary cells often fail to translate effectively into human clinical outcomes. This translational gap slows down drug development and increases the risk of late-stage failures. At DefiniGEN, we provide iPSC-derived wild-type and disease models that offer highly predictive, physiologically relevant human systems for efficacy screening at scale. Our advanced in vitro platforms enable: ✅ More accurate disease modeling – reflecting human biology more closely than traditional models ✅ Enhanced translatability – reducing the risk of failure in clinical trials ✅ Scalable, reproducible testing – optimizing drug screening workflows From #MASLD, #A1ATD, and Urea Cycle Disorders to Wilson’s Disease and intestinal organoids, our models help de-risk drug development and accelerate the path to effective therapies. Discover how DefiniGEN can support your research: https://lnkd.in/e9U6MY6R #DrugDiscovery #EfficacyScreening #iPSC #TranslationalResearch #DiseaseModeling #CellTherapy #stemcells

🚨 Breaking Boundaries in Hepatocyte Functionality 🚨 Did you know that many iPSC-derived hepatocytes lack functional membrane localization and activity of the Asialoglycoprotein Receptor 1 (ASGR1)? This is a critical limitation, but DefiniGEN’s Opti-HEP has changed the game. Our Opti-HEP wild-type hepatocyte model demonstrates robust ASGR1 functionality, setting them apart from other iPSC-derived hepatocytes and even primary hepatocytes, which can only be cultured for up to a week. 💡 Why does this matter? ASGR1 plays a crucial role in hepatocyte-specific endocytosis and clearance processes. Without ASGR1 activity: ❌ Drug metabolism and toxicity studies can lack precision. ❌ Predictive modeling for Drug-Induced Liver Injury (DILI) becomes unreliable. ❌ This culminates in ineffective compounds being selected for clinical trials which go on to fail, costing you time and resources. With Opti-HEP, you can: ✅ Achieve unmatched predictive accuracy in toxicity testing. ✅ Gain confidence in DILI studies, thanks to durable and reproducible functionality. ✅ Optimize research workflows with hepatocytes that deliver consistent performance beyond a week in culture. 👉 Ready to elevate your research? Explore the full potential of Opti-HEP here: https://lnkd.in/dsVg46U3 #iPSC #Hepatocytes #ToxicityTesting #DILI #PharmaInnovation #stemcells #liverdisease #liver

🚨 We’ve published another paper!🚨 We’re proud to announce the publication of our latest paper:   iPSC-derived hepatocytes accurately recapitulate population diversity in alpha-1-antitrypsin deficiency and offer a novel in vitro model for large-scale drug efficacy screening studies Is now available on bioRxiv & medRxiv! This ground-breaking study highlights the power of our iPSC-derived A1ATD in vitro model and how it recapitulates disease pathophysiology and responds to small molecule-based treatments and advanced therapeutic strategies. Our research demonstrates the suitability of this model for large-scale efficacy screening studies for the treatment of A1ATD and help pave the way towards the development of novel therapies. Read the full paper to dive deeper into how our iPSC-derived solutions are transforming research and accelerating breakthroughs: 👉 Read the full paper: https://lnkd.in/d7eVDE39 #DrugDiscovery #iPSC #Hepatocytes #LifeSciences #BiotechInnovation #DefiniGEN #publishedarticle #biorxiv #a1atd #liverdisease

🎓 Celebrating Success: Linda Skiera's Research Journey 🎓 We’re thrilled to announce that Linda Skiera has completed her research project with us at DefiniGEN! With the help of Sophie Trefely’s lab based at The Babraham Institute, over the past five months Linda has been investigating metabolic responses to hormonal stimuli in hepatocytes using iPSC-derived models, working closely with our scientists to generate valuable data for her master’s thesis. Linda joined us as a visiting student from the Technical University of Munich, bringing her passion for #Nutrition and #Biomedicine. Her hard work and dedication in the labs have been truly inspiring, and we’re proud to have supported her on this academic journey. “Thank you to the wonderful team which was always there to help me with any questions I had. I am very grateful that next to this amazing collaboration opportunity, I got a glimpse into the different techniques which are used at DefiniGEN. I am going to miss working with such a brilliant team.” As she moves forward to complete her thesis, we wish Linda all the best in achieving her goals and making impactful contributions to the field of life sciences. 👏 Congratulations, Linda, and thank you for choosing DefiniGEN as part of your journey! #StudentSpotlight #iPSC #Hepatocytes #MetabolicResearch #LifeSciences #FutureLeaders #DefiniGEN #liverdisease #stemcells

Discover how iPSC-derived hepatocytes are transforming drug discovery! In our latest blog post, we delve into four compelling reasons why iPSC-derived hepatocytes overcome the drawbacks seen in primary hepatocytes: ✅ Scalability: Our iPSC-derived hepatocytes, Opti-HEP, are scalable to meet your needs, providing a consistent and unlimited cell source. ✅ Reduced Variability: Derived from a single donor, iPSC lines eliminate batch-to-batch variation inherent in primary cells. ✅ Extended Viability: iPSC-derived hepatocytes maintain functionality over longer periods, unlike primary cells that deteriorate quickly. ✅ Genetic Versatility: iPSCs can be genetically edited to model specific diseases, enhancing research relevance. Read the full article here: https://lnkd.in/erQMrkym #DrugDiscovery #iPSC #Biotech #Pharma #ResearchInnovation #liver #hepatocytes #primarycells #stemcells #liverdisease #toxicityscreening

Discover how iPSC-derived hepatocytes are transforming drug discovery! In our latest blog post, we delve into four compelling reasons why iPSC-derived hepatocytes overcome the drawbacks seen in primary hepatocytes: ✅ Scalability: Our iPSC-derived hepatocytes, Opti-HEP, are scalable to meet your needs, providing a consistent and unlimited cell source. ✅ Reduced Variability: Derived from a single donor, iPSC lines eliminate batch-to-batch variation inherent in primary cells. ✅ Extended Viability: iPSC-derived hepatocytes maintain functionality over longer periods, unlike primary cells that deteriorate quickly. ✅ Genetic Versatility: iPSCs can be genetically edited to model specific diseases, enhancing research relevance. Read the full article here: https://lnkd.in/erQMrkym #DrugDiscovery #iPSC #Biotech #Pharma #ResearchInnovation #liver #hepatocytes #primarycells #stemcells #liverdisease #toxicityscreening